

Limited Distribution Notice for EVRYSDI (risdiplam)

Notice to 340B Covered Entities

August 2020

This notice provides information to 340B covered entities regarding how to acquire EVRYSDI (risdiplam) (NDCs 50242-175-07) at the 340B ceiling price.

EVRYSDI (risdiplam) is a prescription drug indicated for the treatment of Spinal Muscular Atrophy (SMA) in patients 2 months of age and older. EVRYSDI is available in one formulation (60 mg/80mL bottle). Evrysdi was approved for marketing by the US FDA on August 7, 2020 and is available in the US by prescription only.

Genentech has developed a limited distribution model that is applicable to 340B covered entities and all other commercial prescriptions. Genentech makes EVRYSDI available to patients in the following ways:

Prescriptions for EVRYSDI may be filled through the EVRYSDI Specialty Pharmacy Network through Accredo Specialty Pharmacy (1-855-525-7995). 340B covered entities can access 340B ceiling prices for these products through contract pharmacy arrangements with Accredo Specialty Pharmacy. Covered entities in contract pharmacy relationships with Accredo Specialty Pharmacy will be able to follow replenishment procedures in their agreements.

Additional information can be found via Genentech Customer Service at 800-551-223.